Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebamipide for gastric atrophy and intestinal metaplasia after endoscopic resection of early gastric cancer
KCT0007907Phase 4Not yet recruiting
- Sponsor
- Korea Otsuka Pharmaceutical
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in gastritis, atrophic gastritis (AG), Intestinal metaplasia and 1 more comparing Rebamipide with Placebo (2 arms). Planned start Nov 2022; status: not yet recruiting.
02
Drugs
rebamipide
03
Conditions
gastritisatrophic gastritis (AG)Intestinal metaplasiagastric cancer (GC)
Beyond the preview
Go deeper on KCT0007907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007907.